Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author(s):
Kharfan-Dabaja, M.A.; Labopin, M.; Bazarbachi, A.; Socie, G.; Kroeger, N.; Blaise, D.; Veelken, H.; Bermudez, A.; Or, R.; Lioure, B.; Beelen, D.; Fegueux, N.; Hamladji, R.M.; Nagler, A.; Mohty, M.
Published
2015
Publication type
Article / Letter to editor
Acute myeloid leukemiaSecond complete remissionLeukemia-free survivalOverall survivalAllogeneic hematopoietic cell transplantation
Date issued
2015-09-30
Language
English
Is part of
Leukemia Research (2015), Vol. 39, no. 9, p. 933-937
hdl
1887/106595
doi
10.1016/j.leukres.2015.04.009